Merck and Covid has announced a partnership to develop a vaccine to prevent tetanus, a disease that is a serious risk in many countries, and that has been linked to autism and other serious diseases.

The vaccine, which will be called the Merck Covid–19 Vaccination, is being developed with Merck’s Covid Vaccine Center in San Diego, California, which is one of several centers in the US dedicated to developing vaccines for the disease.

The new vaccine will be manufactured by Covid Labs in Los Angeles, which has been using the Covid vaccine in the production of other vaccines for other conditions.

It is the first time that Merck has partnered with a non-Merck company to develop and manufacture a vaccine.

Merck did not disclose the total cost of the vaccine, but the company said it will cover the cost of developing and manufacturing the vaccine.

It said that, in addition to the Covids, it will also make vaccines for hepatitis B, HIV and other diseases.

Merks co-founder and CEO John Anderson said in a statement that the partnership is a major step forward for the future of vaccines.

He noted that Merk has previously partnered with Covid on other vaccines, including with the Hepatitis B vaccine.

The Covid vaccines are used to prevent the virus that causes the disease, which kills up to 80% of those who have it.

“This partnership will give our vaccine to patients who otherwise would not have access to the vaccine,” Anderson said.

The Merck partnership comes after a series of vaccine setbacks in recent years.

In 2014, the Covis-19 vaccine was pulled from the market because of safety concerns.

And earlier this year, the FDA said that Merks Covid was not approved for use in humans, a decision that led to a recall of more than a million cases of the Covirus-19 in the United States.

The FDA also said that a new vaccine developed by Covids vaccine partner, Sanofi Pasteur, was found to be more effective in protecting the elderly than Covid, a finding that was widely criticized.

The Centers for Disease Control and Prevention estimates that more than 4.5 million Americans were infected with the Covidenci-19 strain of the virus in 2014.

But that number has not been updated since then, and the CDC has said that the vaccine is still not effective.

In February, Covids parent company Novartis said it was canceling a deal with Covids to manufacture the Covdac vaccine, citing safety concerns about the vaccine’s safety.

The announcement came after the CDC released a report concluding that the Covindax vaccine, developed with Coviddis, is more effective than the Covydac vaccine and that it is less likely to cause adverse events.